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Opinion statement
Low testosterone levels are frequently observed among men with treated and
untreated HIV infection. However, the interpretations of biochemical measurements
of testicular function are challenging and need to be considered in the context of
the clinical presentation and scenario. The distinction between primary and second-
ary hypogonadism and determination of the underlying clinical pathophysiology are
not always straightforward. Early recognition of clinical hypogonadism and appro-
priate treatment may improve clinical outcomes and quality of life for affected
individuals. A principal aim of testosterone replacement is to maintain serum
testosterone concentrations in the normal physiological range and should be con-
sidered in clinically symptomatic patients.
Introduction
Hypogonadism commonly affects HIV-positive men
and is associated with a variety of clinical symptoms
adversely affecting quality of life. However, symp-
toms of hypogonadism may be non-specific and at-
tributed to a variety of causes, making the diagnosis
challenging. An association between HIV infection
and hypogonadism has long been recognised, partic-
ularly among those with advanced immuno
suppression [1–3]. Although the introduction of
anti-retroviral therapy (ART) has lowered the
incidence of hypogonadism among HIV infected
men, it remains an issue, and interpretation of bio-
chemical results and presentation is not straightfor-
ward. This article reviews the clinical features and
diagnosis of hypogonadism in HIV-infected adult
men, illustrated with a series of clinical case
descriptions.
Clinical features of male hypogonadism
Common symptoms of hypogonadism in adult men include fatigue, low
mood, reduced libido and erectile dysfunction [4••, 5, 6]. Less frequent com-
plaints include reduced muscle mass, loss of body hair, weight loss, poor sleep,
reduced concentration, memory difficulties and increased risk of osteopenia.
Physical signsmay include loss of axillary and pubic hair, testicular atrophy and
gynaecomastia, but these features may be absent among men who develop
hypogonadism during adult years, in contrast to pre-pubertal males with
hypogonadism where secondary sexual characteristics are undeveloped. Clini-
cal symptoms are not pathognomonic and may indicate other underlying
conditions including psychosexual disturbance, diabetes mellitus, neurological
disease, chronic hepatitis C virus infection, adverse drug effects (recreational
and prescribed), smoking and vitamin D deficiency.
Pathophysiology
Testosterone is produced by Leydig cells in the testes under stimulation by
luteinising hormone (LH) which drives testosterone secretion and follicle-
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Fig. 1. Male hypothalamic-pituitary-gonadal axis
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stimulating hormone (FSH), which drives spermatogenesis. Gonadotropins
produced by the anterior pituitary gland are regulated by hypothalamus-
produced gonadotropin releasing hormone (GnRH). Testosterone inhibits go-
nadotropin production by direct negative feedback (Fig. 1). Male
hypogonadism is the clinical syndrome resulting from the failure of the testes
to produce sufficient physiological levels of testosterone (androgen deficiency)
and/or reduced numbers of sperm, as a consequence of disruption of the
hypothalamic-pituitary-testicular axis. Hypogonadism can be classified into
primary hypogonadism as a result of primary testicular disease or secondary
hypogonadism as a result of a central defect of the hypothalamus or pituitary
gland (Table 1). Distinguishing primary and secondary hypogonadism is read-
ily made by measurement of the serum gonadotropins (LH and FSH). In
primary hypogonadism, LH is elevated due to loss of negative feedback, whilst
in secondary hypogonadism, LH is inappropriately normal or low.
Biochemical measurements
Regardless of HIV status, the first-line investigation to confirm hypogonadism
in adult men is the measurement of early morning serum total testosterone
between 8 a.m. and 10 a.m. to account for the diurnal variation of testosterone
concentrations which peaks during morning hours [7]. As acute illness may
cause transient secondary hypogonadism, men should not be investigated for
hypogonadism until the inter-current illness has resolved. Low measurements
of total testosterone concentrations are required on at least two separate occa-
sions to confirm hypogonadism.
Serum testosterone circulates in two forms: as protein-bound to sex
hormone-binding globulin (SHBG) or as biologically active free testosterone.
Routine laboratory assays measure total serum testosterone levels via immuno-
assay rather than the free hormone; therefore, interpretation must take into
Table 1. Causes of primary and secondary hypogonadism
Primary hypogonadism Secondary hypogonadism
Congenital Klinefelter’s syndrome




Isolated GnRH deficiency (Kallmann syndrome)
GnRH deficiency syndrome (genetic disorders with obesity and
learning disability)
Acquired Infection of testis, e.g. mumps
Radiation
Drugs: ketoconazole, suramin, cytotoxic
agents
Corticosteroids
Testicular trauma or torsion
Auto-immune damage to testis
Chronic systemic illness including cirrhosis,
renal failure, AIDS wasting
Pituitary tumours including adenoma, craniopharyngioma,
meningioma, glioma, metastatic deposits
Exogenous androgen administration
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account the full clinical and biochemical picture. Measurement of free testos-
terone is possible via tandemmass spectrometry and is increasingly favoured in
academic publications relating to sex steroid measurement, but as it is labour
intensive and expensive, it is not currently used in routine clinical practice.
Abnormalities in SHBG can influence the total serum testosterone reading
[8], because a low SHBG will lead to a low total testosterone level, even though
the free hormone concentration may be normal. Conversely, if the SHBG is
elevated, serum total testosterone levels may appear to be within the normal
range, despite the fact that free testosterone may actually be low and causing
clinical hypogonadism. There are recognised equations that calculate estimated
free testosterone concentrations based on albumin, SHBG and total testoster-
one concentrations which are readily available online [9].
Causes of increased SHBG concentrations include physiological ageing,
hypothyroidism, elevated oestrogen levels, chronic liver disease and cirrhosis,
HIV infection and drugs that affect liver function. Causes of decreased SHBG
concentrations include obesity, insulin resistance and type 2 diabetes mellitus,
exogenous androgen, anabolic steroid or glucocorticoid use and nephrotic
syndrome. Awareness of the role of SHBG is pertinent to HIV clinicians, as
serum SHBG levels are often abnormal in HIV-infected patients [10•]. SHBG
may be significantly elevated resulting in normal measurements of total testos-
terone concentrations, despite low free testosterone levels. Obesity, diabetes
and insulin resistance are common reasons for reduced SHBG in HIV patients
on treatment, which lowers the serum total testosterone concentration often
without affecting free testosterone; weight reduction will correct the binding
abnormality.
Once androgen deficiency has been established, measurement of gonado-
tropin concentrations (LH and FSH) will distinguish primary from secondary
hypogonadism. Elevated LH and FSH concentrations indicate primary
hypogonadism, i.e. normal hypothalamic and pituitary function with impaired
testicular function. Normal or suppressed LH in the presence of testosterone
deficiency indicates secondary hypogonadism.
Primary hypogonadism
Primary hypogonadism is more likely to be associated with gynaecomastia as
the stimulatory effects of elevated serum LH and FSH concentrations on the
testis increase conversion of testosterone to oestradiol. Primary hypogonadism
may be due to congenital abnormalities or acquired disease. Adult HIV clini-
cians are not likely to diagnosis congenital primary hypogonadism; however, it
is worth noting that Klinefelter’s syndrome, characterised by presence of an
extra X chromosome (47XXY genotype), is one of the commonest congenital
abnormalities to cause primary hypogonadism affecting 1 in 1000 male births
[11]. The classical Klinefelter’s phenotype of small testes, increased long bones,
psychosocial and learning difficulties is straightforward, but other mosaicisms
with lesser numbers of X chromosomes may result in minimal and previously
unrecognised clinical features and can present in sexually active men. Diagnosis
is made by determination of the karyotype of the peripheral leucocytes.
Acquired primary hypogonadism is often idiopathic with no clear aetiology.
HIV-infected patients are at increased risk of any solid organ and haematological
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malignancies, including those with gonadal involvement [12]. Testicular ultra-
sound scanning may be needed to identify local abnormalities. Medical oncol-
ogy treatments including local radiotherapy (e.g. to inguinal nodes for lympho-
ma) and exposure to alkylating or anti-neoplastic agents can damage testicular
tubular cells. Opportunistic infection of the testes is usually clinically apparent
and rare with CD4 count 9100 cells/mm3, but Mycobacterium tuberculosis, Myco-
bacterium avium, Treponema pallidum and fungal pathogens (Cryptococcus spp.,
Blastomycosis spp.) can cause orchitis [13–16]. Reduced testosterone production
can follow mumps orchitis, particularly if the infection is bilateral and is
contracted in adulthood [17]. Following unwarranted safety concerns of child-
hood MMR vaccine during the late 1990s, vaccine uptake and coverage rates fell
to low levels leading to current re-emergence of mumps infections. HIV infection
is known to upregulate tumour necrosis factor and interleukin-1 [18]; both
cytokines are linked with decreased testicular steroidogenesis. Autoimmune
damage, often in association with thyroid and adrenal insufficiency, may occur
driven by cytokine-related inflammation or development of anti-sperm antibod-
ies. Men affected by chronic medical conditions such as liver cirrhosis and end-
stage renal disease have an increased incidence of reduced total testosterone
concentrations, although suppression of LH and FSH responses in some patients
suggests secondary effects may also be contributing [19, 20].
Secondary hypogonadism
Normal or suppressed gonadotropin concentrations in the presence of low
serum testosterone indicate hypothalamic-pituitary dysfunction or secondary
hypogonadism; this is the most common cause of hypogonadism among HIV-
infected men [6, 21].
Disease processes affecting the hypothalamus or pituitary (stalk or gland) can
suppress GnRH or gonadotropin secretion, respectively. This may be due to
damage to either hypothalamic or pituitary areas from tumours which can be
benign (typically causing symptoms by direct compression or by secretion of
excess prolactin from pituitary adenomas), primary or metastatic malignant
diseases including central nervous system (CNS) lymphoma. Pituitary apoplexy
occurs when there is sudden haemorrhage and necrosis into a pre-existing
pituitary adenoma, causing pan-hypopituitarism and symptoms associated with
mass effect (headache, visual field disturbance). In patients with HIV infection or
immunosuppression, lymphoma or syphilis of the pituitary can precipitate or
mimic apoplexy [22, 23], and meningeal or pituitary infection with
M. tuberculosis, Toxoplasma gondii, Pneumocystis jirovecii, cytomegalovirus (CMV)
or candidiasis may result in fibrosis and gradual loss of function [24–26]. Non-
infective infiltrating conditions that can cause secondary hypogonadism include
sarcoidosis, histiocytosis or iron deposition due to haemochromatosis. The
presence of diabetes insipidus may suggest an infiltrative pituitary lesion.
Secretion of gonadotropins may be suppressed not only by specific drugs,
such as GnRH antagonists used in prostatic cancer treatment, but also by the use
of exogenous androgens (anabolic-androgenic steroids) for recreational body
building. HIV-infected men using exogenous androgens to enhance their body
image may not admit to their usage, but also be reluctant to withdraw. Drugs,
such as stanozolol, suppress gonadotropin secretion and testicular function.Over
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time, testicular volumemay decrease, resulting in impaired infertility. Spermato-
genesis, gonadotropin and testosterone secretion remain suppressed for several
months after discontinuation, before usually returning to normal [27]. Other
medications can suppress gonadotropin secretion, in particular chronic cortico-
steroid use (e.g. for inflammatory conditions) or opiates including methadone
replacement.
Obese patients and those with diabetes or insulin resistance tend to
have lower SHBG concentrations and therefore lower serum concentra-
tions of total testosterone [28]. Free testosterone concentrations may be
abnormally low, with normal LH and FSH indicating secondary effects.
Lifestyle changes and weight reduction generally improve serum testoster-
one levels. Sex hormone abnormalities appear to play a role in the path-
ogenesis of insulin resistance and diabetes mellitus in HIV-infected men
[29]. Chronic medical conditions including not only HIV infection but
also liver cirrhosis, chronic hepatitis C virus infection and renal failure are
associated with low testosterone levels and hypogonadism by combination
of primary and secondary effects.
Hypogonadism in HIV-infected men
Hypogonadism is common among HIV-infected men, although the true prev-
alence remains poorly defined and widely ranging from G10% [30–32] to over
50% [3, 6, 21] in different studies. Before the widespread use of ART, androgen
deficiency was the most common endocrine abnormality detected, with low
serum testosterone levels in up to 70% of HIV-infected men, with strong
associations to lowCD4 count (G100 cells/mm3), weight loss and AIDSwasting
[1–3, 21]. Of these hypogonadal HIV-infectedmen, around 75%had secondary
hypogonadism. As inter-current illnesses suppress gonadotropin secretion, low
serum testosterone concentrations in AIDSmay reflect active inflammation and
disease and overestimate the frequency of hypogonadism. However, studies of
symptomatic HIV-infected men, including those receiving ART, also identify
low serum testosterone levels in up to 30%, and this is associated with weight
loss, muscle wasting with loss of strength and depression [1, 2, 31–33] with
levels rising after ART [30]. Conversely, an observational cohort study
(CHAMPS) conducted in New York compared testosterone concentrations in
502 HIV-infected and HIV-negative men aged 949 years [6] and found that HIV
infection was not associated with low total testosterone levels. However, among
HIV-infected men, uncontrolled HIV viraemia (910,000 copies/ml) was strong-
ly linked to hypogonadism (mainly secondary), with psychotropic and
injecting drug use, chronic hepatitis C virus infection and obesity.
Wide-ranging estimates of androgen deficiency are likely to be influenced by
SHBG abnormalities in HIV-infected men [29, 31] and available biochemical
assays. Free, rather than total testosterone concentration, is a preferred measure,
but as previously described, assays are not readily available [10]. Further, low
serum testosterone is associated with poor health status in HIV-infected men,
with the risk of biochemical hypogonadism cumulatively rising with number of
co-morbidities and frailty index scores, raising a suggestion that low testoster-
one concentrations could be an adaptive change to chronic ill health and reflect
ongoing inflammation [33].
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Overall, the cause of hypogonadism and low testosterone in HIV-infected
men is likely to be multi-factorial related to co-morbidities, chronic inflamma-
tion, illicit drug and ART use and body composition changes. Our clinical cases
illustrate some of the causes specific to HIV-infected men that may be encoun-
tered during clinical practice.
Case studies
Case 1: primary hypogonadism
A 57-year-old HIV-infected man who attended for routine HIV clinical review
described increased fatigue, reduced libido and erectile dysfunction unrespon-
sive to phosphodiesterase-5 inhibitor use. He had stable type 2 diabetes
mellitus (controlled by metformin 1 g b.d). He presented 2 years earlier with
pulmonary tuberculosis and HIV-1 infection with nadir CD4 count 50 cells/
mm3 and viral load 9100,000 copies/ml. His HIV infection was well controlled
(CD4 540 cells/mm3, viral load G40 copies/ml) by Maraviroc 300 mg b.d. and
Kivexa (abacavir 600mg/lamivudine 300 mg o.d.). Physical and genital exam-
ination was normal. Investigations included early morning total testosterone
6.2 nmol/l (normal range 9.4–37 nmol/l), calculated free testosterone
142 pmol/l (normal range 174–729 pmol/l), LH 16 IU/ml (normal range 1–
9 IU/ml), FSH 24 IU/ml (normal range 1–10 IU/ml) and SHBG 22 nmol/l
(normal range 15–40 nmol/l). A diagnosis of primary hypogonadism was
made. Topical testosterone treatment (Testogel, one sachet per day) was initi-
ated with resolution of symptoms.
Case 2: primary hypogonadism with drug-induced elevated SHBG
A 54-year-old male, diagnosed with HIV-1 infection 8 years earlier, was well
controlled on Atripla (efavirenz 600 mg/emtricitabine 200 mg/tenofovir
disoproxil 245 mg) with CD4 count 370 cells/mm3 and viral load
G40 copies/ml presented with fever, weight loss and shortness of breath. Chest
imaging found a large left pleural effusion with left lower lobe consolidation.
Fully sensitive M. tuberculosis was isolated from pleural specimens. He
responded to standard anti-tuberculosis treatment (rifampicin, isoniazid,
pyrazinamide and ethambutol). Atripla was continued with additional
efavirenz 200 mg o.d. to overcome predicted rifampicin-efavirenz drug interac-
tion. After 2 months, he developed marked reduction in libido with erectile
dysfunction. Investigations found serum total testosterone 11 nmol/l, SHBG
170 nmol/l, calculated free testosterone 60 pmol/l, LH 14 IU/ml and FSH
15 IU/ml. Efavirenz has a direct oestrogenic effect by modulating oestrogen
receptors [34], and this effect may have been exacerbated by SHBG elevation
(HIV infection, anti-tuberculosis treatment and ART) reducing free testosterone
concentrations, despite normal total levels. After additional efavirenz was
discontinued, SHBG returned to normal and his clinical symptoms fully
resolved.
Case 3: opportunistic HIV-related tuberculous CNS infection leading to pituitary dysfunction
A 51-year-old male with stable HIV infection (current CD4 350 cells/mm3, viral
load G40 copies/ml) managed on Triumeq (dolutegravir 50 mg/abacavir
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600 mg/lamivudine 300 mg) had been diagnosed 9 years earlier when present-
ing with disseminated tuberculosis (sites of involvement: pulmonary, renal,
meningeal). He also had sero-positive rheumatoid arthritis. He described on-
going lethargy, fatigue and loss ofmuscle strength. Serum total testosterone was
2.1 nmol/l, calculated free testosterone 46.1 pmol/l, LH 5 IU/l, FSH 10 IU/l,
SHBG 21 nmol/l, thyroxine 13 pmol/l (normal range 9–25 pmol/l), cortisol
394 nmol/l (normal range 138–620 nmol/l) and prolactin 74 mIU/l (normal
range 50–400 mIU/l). Magnetic resonance imaging (MRI) of the pituitary
found a low volume pituitary gland with hypointense parenchyma consistent
with healed granulomatous lesion (Fig. 2). Symptoms resolved following in-
tramuscular testosterone replacement.
Case 4: pituitary haemorrhage from direct CMV infection
A 49-year-old man presented with sudden confusion and headache. He was
diagnosed HIV-positive (CD4 220 cells/mm3, viral load 3898 copies/ml)
with acute kidney injury and CMV viraemia. Computerised tomography
(CT) brain imaging was normal. He received once daily lamivudine
300 mg, darunavir 800 mg and ritonavir 100 mg with raltegravir 400 mg
b.d. He developed symptomatic hypotension. Testosterone was G0.3 pmol/l
with biochemical features of panhypopituitarism with cortisol G25 nmol/l,
free thyroxine 4.6 pmol/l, TSH G0.05 IU/l, prolactin G10 mIU/l, LH 1.2 IU/l
ba
Fig. 2. Case 3 (pituitary fibrosis secondary to tuberculous CNS infection). a Coronal MRI showing low volume pituitary gland. b
Sagittal MRI showing low volume pituitary gland and probable pituitary fibrosis
ba
Fig. 3. Case 4 (suspected HIV-related pituitary haemorrhage). a Coronal MRI at presentation showing likely haemorrhage within
enlarged pituitary gland. b Six-month follow-up MRI showing reduction in pituitary size with concave upper border
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and FSH G0.5 IU/l. Cerebrospinal fluid (CSF) analysis revealed a raised
protein (0.66 g/l) and negative microscopy. MR imaging found evidence
of subacute haemorrhage in the pituitary gland, with no evidence of pitu-
itary tumour, suggesting direct haemorrhage into the gland, which is un-
usual (Fig. 3). The working diagnosis was CMV infection of the pituitary
gland causing haemorrhage [26]. His hypopituitarism was treated by ap-
propriate endocrine replacement with hydrocortisone, levothyroxine and
testosterone.
Case 5: exogenous anabolic steroid use
A 49-year-old heterosexual man who was diagnosed with HIV infection 3 years
earlier following screening when hospitalised for pneumococcal pneumonia
was managed with once daily darunavir 800 mg, ritonavir 100 mg and
emtricitabine 200 mg/tenofovir disoproxil 245 mg. His current CD4 level was
370 cells/mm3 and viral load was G40 copies/ml. He trained regularly at the
gym and was a keen amateur boxer. He wished to conceive with his wife but
complained of lack of energy and reduced libido. Serum total testosterone levels
were 5.5 pmol/l, calculated free testosterone 150 pmol/l, SHBG 14 nmol/l, FSH
4 IU/ml, LH 5 IU/ml and prolactin 89 mIU/ml. He admitted to regular use of
oxandrolone and stanozolol over several years.
Discussion of cases
These cases represent a range of real-life clinical scenarios whereby patients have
low testosterone concentrations and HIV infection. Primary hypogonadism, as
illustrated by case 1, is readily recognised by the presence of elevated LH levels
which makes the decision to treat with testosterone straightforward, as it is clear
that the pituitary is trying to compensate for the low testosterone. Whilst it is not
possible to identify whether his HIV infection or an alternative pathology caused
the primary hypogonadism, the patient clinically responded to testosterone
replacement. Case 2 is an important learning point as efavirenz appeared to
cause reversible symptoms of hypogonadism. The hypothesis is that efavirenz-
induced oestrogen antagonism, in addition to a drug-induced elevation of SHBG
reducing circulating free testosterone levels. Dose reduction improved both
SHBG abnormalities and resolved the clinical symptoms. This shows the impor-
tance of interpreting serum testosterone levels in the context of drug therapy and
clinical scenario. Cases 3 and 4 illustrate the potential for HIV-associated oppor-
tunistic infections to directly cause hypothalamic-pituitary pathology. In case 3, it
is likely that CNS tuberculosis caused pituitary disease leading to a shrunken
fibrotic gland (Fig. 2). The unusual MRI appearance in case 4 of a haemorrhagic
pituitary gland in the absence of a pituitary tumour suggests direct CMV infection
of the gland, which has been previously described [26] (Fig. 3). Case 5 illustrates
how exogenous androgenic steroid use suppresses testosterone concentrations,
but may not be volunteered by the patient unless specifically questioned.
Clinical management
Once hypogonadism has been confirmed and evaluated (Fig. 4), appropriate
testosterone replacement should be considered. The aims of treatment are to
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improve clinical symptoms, reduce the risk of osteoporosis andmaintain serum
testosterone concentrations in the normal healthy male reference range. The
main long-term consequence of untreated true hypogonadism is reduced bone
density and osteoporosis, which may be compounded by the use of tenofovir
disoproxil which is also associated with bone demineralisation [35]. Dual-
energy X-ray absorptiometry (DEXA) scanning to assess bone density is recom-
mended in HIV-positive men over 70 years of age or in those over 50 years who
have additional risk factors such as previous bone fracture, chronic hepatitis
virus co-infection or hypogonadism [36].
Systematic review of randomised, double-blinded placebo-controlled studies
assessing testosterone replacement among androgen-deficient HIV-infected men
with weight loss has found significant increases in measured fat-free mass, lean
body mass and muscle mass [37•]. Fifty-one HIV-infected men (mean age
42 years) with wasting were randomised to intramuscular testosterone or placebo
for 6 months [38]. Those men receiving androgen therapy had significant in-
creases of 1.9, 2 and 2.4 kg in lean body mass, fat-free mass and muscle mass,
respectively. Transdermal testosterone replacement, for 3months, among 41HIV-
infected men aged 18–60 years with weight loss increased lean body mass by
1.35 kg as compared to placebo [39]. The clinical significance of small gains in
lean bodymass is unclear, although secondary endpoints such asmuscle strength,
fatigue,mood and health-related quality of life scores are generally improved [39–
42]. Furthermore, whilst well tolerated with no observed adverse effects on CD4
orHIV viral load control, studies of testosterone replacement in HIV-infectedmen
have been of relatively short duration (3–6 months), so long-term benefits and
potential adverse effects of therapy are unclear. Current Endocrine Society clinical
practice guidelines suggest at least short-term testosterone therapy as adjunctive
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Fig. 4. Evaluation of patient with hypogonadism. Asterisk indicates free testosterone if available
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therapy in HIV-infectedmen with weight loss and low testosterone levels in order
to promote gain in muscle strength and lean body mass [4••].
Testosterone replacement may cause growth in androgen-sensitive malignan-
cies such as prostatic or breast and is infrequently associated with polycythaemia.
Monitoring of serumhaematocrit and prostate gland via digital rectal examination
and serum prostate-specific antigen levels is recommended whilst on testosterone
replacement. Other adverse reactions include local skin reactions from topical
therapy or injection site reactions.
In summary, symptoms of hypogonadism and low testosterone levels are
common in HIV-infected men and are frequently overlooked. Interpretation of
biochemical testing is challenging. Once confirmed, causes of hypogonadism
should be investigated and appropriate treatment may be needed.
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